In an interview with Pharmacy Times, Ali A. Habib, MD, clinical professor of neurology at the University of California, Irvine, discusses what the hospitalization findings mean for patients and why they should be viewed as supportive evidence
Commentary|Videos|March 10, 2022
What Pharmacists Should Understand When Assessing, Treating Patients With Ovarian Cancer With Rucaparib
Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses what oncology pharmacists should understand about rucaparib when treating ovarian cancer.
Advertisement
Pharmacy Times interviewed Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, on what rucaparib is used to treat and how its mechanism of action works to fight cancer.
During the interview, Morris addressed what oncology pharmacists should understand when assessing and treating patients with ovarian cancer with rucaparib.
Advertisement
Related to this article
In an interview with Pharmacy Times, City of Hope researchers discuss a preclinical platform designed to redirect CAR T cells after infusion and how pharmacists could help bring this adaptable approach into clinical practice.
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
The FDA approval of pritelivir offers an oral treatment for refractory HSV lesions in immunocompromised adults, with drug interactions creating an important role for pharmacists.
Weltruza, the first subcutaneous long-acting injectable (LAI) formulation of olanzapine, requires no loading doses, oral supplementation, or postinjection monitoring.
Sometimes, a breakthrough matters not only because of what it does for patients today, but because of what it makes possible for tomorrow.
Patients reported that zongertinib resulted in improvements in physical functioning within 1 week of initiating therapy.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia
2
Pneumonic Plague: What Pharmacists Need to Know About Treatment
3
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
4
FDA Approves Pritelivir for Refractory HSV Lesions in Immunocompromised Adults
5